in patients who are at target is more effective in lowering infection risk while maintaining disease control than continuation of rituximab. The recommendation is conditional because physician and patient risk tolerance is likely to vary depending on the degree of hypogammaglobulinemia and patient-specific risk factors for infection. Previous serious infection Addition of csDMARDs is conditionally recommended over addition of a bDMARD or tsDMARD for patients with a serious infection within the